The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling

Phase 1 (Common Cancer Early Detection - CCANED) Inclusion Criteria: * Age: Adults aged 40 years or older. * Confirmed diagnosis of one of the following common cancers: Non-Small Cell Lung Cancer (NSCLC), Glioblastoma Multiforme (GBM), Colorectal Cancer, Hepatocellular Carcinoma (HCC), Breast Cancer, Prostate Cancer, Ovarian Cancer, Pancreatic Cancer. Exclusion Criteria: * Currently pregnant. * Presence of any active infectious diseases. * Use of anticoagulant or antiplatelet drugs within the past 2 weeks. * Any medical or psychological conditions that may affect the participant's ability to comply with study procedures. Phase 2 ( Cancer Immuno-Profiling of Hematologic and Extracellular RNA - CIPHER) Inclusion Criteria: * Adults aged 40 years or older. * Confirmed diagnosis of: Hepatocellular Carcinoma (HCC), Non-Small Cell Lung Cancer (NSCLC) * Willingness to provide blood samples at the specified intervals (baseline, 6 weeks, and 6 months post-therapy initiation). Exclusion Criteria: * Presence of another malignancy unless it has been in remission for at least 5 years. * Significant uncontrolled co-morbid conditions that may interfere with study participation or outcomes.